MedDataX Logo

Multi-center Study on Therapy-oriented Molecular Subtyping of Hepatocellular Carcinoma

NCT ID: NCT03668158

Last Updated: 2018-10-24

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

UNKNOWN

Total Enrollment

500 participants

Study Classification

OBSERVATIONAL

Study Start Date

2018-11-20

Study Completion Date

2020-07-01

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The purpose of this study is to establish molecular subtyping of HCC.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

29-Gene Liver Cancer Subtype and Immunotherapy Effectiveness

NCT07100236

Primary Hepatocellular Carcinoma
NOT_YET_RECRUITING

A Study to Evaluate Safety and Efficacy of Armored CAR-T Cell Injection C-CAR031 in Advanced Hepatocellular Carcinoma

NCT05155189

Hepatocellular Carcinoma
RECRUITING PHASE1

Study on the Classification of Comprehensive Treatment Effect of Hepatocellular Carcinoma

NCT06542796

Hepatocellular Carcinoma Immunotherapy
RECRUITING NA

Identification and Prognostic Value of Key Genes in Hepatocellular Carcinoma

NCT05759858

Hepatocellular Carcinoma
RECRUITING

Combined Immunotherapy and Targeted Therapy for Hepatocellular Carcinoma

NCT04152356

HepatoCellular Carcinoma
UNKNOWN

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Hepatocellular carcinoma is one of the most common malignant tumors in the world with high incidence and mortality. Liver transplantation is the most effective treatment for HCC and is in high demand in China. However, recurrence of HCC among liver transplantation recipients is still a great challenge and threat to the survival of recipients. So it is of great significance to establish molecular subtyping of HCC and achieve precise selection of recipients. Based on large scales of samples, the investigator's study aims to establish multi-omics characteristic profiles of liver transplantation for HCC in integration of apparent biological characteristics, clinical management and prognostic information by utilizing genomics, transcriptomics and proteomics, etc. This study will contribute to the therapy-oriented molecular subtyping of HCC.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Hepatocellular Carcinoma

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

COHORT

Study Time Perspective

RETROSPECTIVE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

recurrent HCC

recurrent HCC after LT

No interventions assigned to this group

non-recurrent HCC

non- recurrent HCC after LT

No interventions assigned to this group

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

Liver transplantation due to HCC within Hangzhou criteria

Exclusion Criteria

Liver transplantation due to HCC beyond Hangzhou criteria Liver transplantation due to other disease except HCC Multiple organ transplantation
Minimum Eligible Age

18 Years

Maximum Eligible Age

70 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Zhejiang University

OTHER

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Xiao Xu

Clinical Professor

Responsibility Role PRINCIPAL_INVESTIGATOR

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

ZJHZXU2017

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.

Study of Durvalumab Plus Tremelimumab as First-line Treatment in Chinese Patients With Unresectable Hepatocellular Carinoma
NCT05557838 RECRUITING PHASE3
A Study of Chromosomal Abnormalities as a Predictor of Staging and Prognosis in Patients With Liver Cancer
NCT05371873 UNKNOWN
A Study of Chimeric Antigen Receptor T Cells Combined With Interventional Therapy in Advanced Liver Malignancy
NCT02959151 UNKNOWN PHASE1/PHASE2
Efficacy of Target - Immunotherapy and XELOX Chemotherapy for Advanced HCC
NCT06818097 COMPLETED
Immune Checkpoint Inhibitors and Anti-vascular Endothelial Growth Factor Antibody/tyrosine Kinase Inhibitors with or Without HAIC for Advanced HCC
NCT06881433 RECRUITING
Immune Checkpoint Inhibitor Monotherapy or Combined With Molecular Targeted Drugs / Locoregional Therapy in the Treatment of Hepatocellular Carcinoma
NCT05609695 UNKNOWN
Gecacitinib Combined With Donafenib and PD-1 Inhibitor as Immune Rechallenge Therapy for Unresectable Hepatocellular Carcinoma
NCT07157306 NOT_YET_RECRUITING PHASE2
A Study on the Heterogeneity of Efficacy of Interventional Therapy Combined With Systemic Therapy for Liver Cancer Based on Multi-center Real-world Data
NCT07156617 NOT_YET_RECRUITING
Study on the Efficacy and Safety of Transarterial Chemoembolization Combined with Targeted Immunotherapy in Patients with Unresectable Hepatocellular Carcinoma
NCT06715072 NOT_YET_RECRUITING
Cabozantinib in Hepatocellular Carcinoma
NCT04588051 ACTIVE_NOT_RECRUITING PHASE2
Application of Integrated Proteomic and Serum Metabolomic Analysis in Assessing the Efficacy and Prognosis of TACE Combined With Targeted Immunotherapy in Unresectable Hepatocellular Carcinoma
NCT06540508 ENROLLING_BY_INVITATION
A Study of SCG101 TCR-T Cell Therpay in the Treatment of Subjects With Hepatitis B Virus-Related
NCT06617000 RECRUITING PHASE1
Conversion or Neoadjuvant Therapy in Hepatocellular Carcinoma
NCT06405321 RECRUITING
The Value of 68Ga-FAPI PET/CT in the Efficacy Evaluation of Advanced Unresectable Hepatocellular Carcinoma Patients Undergoing Systemic Antitumor Therapy
NCT06746194 RECRUITING
ICIs With and Without MWA in Advanced Hepatocellular Carcinoma
NCT06581497 COMPLETED
Study on Effectiveness and Safety of Hepatocellular Carcinoma Patients Treated With CyberKnife
NCT02363218 UNKNOWN PHASE2
Regorafenib Alone or in Combined With Transcatheter Arterial ChEmoembolization in Treatment of Advanced Hepatocellular Carcinoma After First Line Targeted Therapy
NCT05811481 RECRUITING
Real-world Study for Patients With Advanced Hepatobiliary Tumors
NCT03892577 RECRUITING
Immunogenomic Dynamics and Biomarkers in Patients With Hepatocellular Carcinoma Receiving Immunotherapy
NCT07186010 RECRUITING
The Efficacy of Transarterial Chemoinfusion (TAI) Combine Stereotactic Body Radiation Therapy (SBRT) in Unresectable Hepatocellular Carcinoma (HCC)
NCT03851887 UNKNOWN PHASE2
Plasma Biomarker in Predicting Response and Toxicity in HCC Patients Treated With Checkpoint Inhibitors With or Without SBRT
NCT06408753 COMPLETED
TCR-Redirected T Cells Therapy in Patient With HBV Related HCC
NCT03899415 UNKNOWN PHASE1
The Efficacy of Transarterial Chemoinfusion (TAI) Combine Toripalimab in Advanced Hepatocellular Carcinoma (HCC)
NCT03851939 UNKNOWN PHASE2
Efficacy and Safety of Donafenib in Patients With Advanced Hepatocellular Carcinoma
NCT02645981 COMPLETED PHASE2/PHASE3
Evaluate the Treatment With Sintilimab Injection Plus Endostar in Hepatocellular Carcinoma
NCT03881501 UNKNOWN